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ABSTRACT
Objectives: Case reports of capecitabine cardiotoxicity
resemble those seen with intravenous 5-fluorouracil
(5-FU) with chest pain as the predominant
manifestation, but few studies of capecitabine
cardiotoxicity are available. We aimed to determine the
incidence of symptomatic cardiotoxicity from
capecitabine in patients with breast cancer and to
identify risk factors.
Methods: We reviewed medical records of
consecutive women with breast cancer treated with
capecitabine (1000 mg/m2 two times per day) from
2002 to 2012 at one institution.
Results: 22 of 452 patients (4.9%) (95% CI 2.9% to
6.9%) had symptoms of cardiotoxicity (chest pain:
n=13, dyspnoea: n=9, palpitations: n=2). 11 patients
had changes on ECG (atrial fibrillation: n=5, ST
deviations: n=3, T-wave abnormalities: n=2 and QTc
prolongation: n=1). 2 patients (0.4%) sustained acute
myocardial infarction. 1 patient (0.2%) developed
cardiac arrest with lethal outcome. 4 of 6 patients
(66%) retreated with capecitabine had recurrent
symptoms at retreatment. Cardiac comorbidity
(p=0.001), hypercholesterolaemia (p=0.005) and
current smoking (p=0.023) were risk factors for
cardiotoxicity in univariate analyses and remained
significant when adjusted for age. Patients with cardiac
comorbidity were 5.5 times (95% CI 2.0 to 14.8) more
likely to develop cardiotoxicity. In the subgroup of
patients with apparently no cardiac comorbidity, the
incidence of cardiotoxicity was lower (3.7%) and
hypercholesterolaemia (p=0.035) and current smoking
(p=0.020) were risk factors of cardiotoxicity.
Conclusions: The incidence of cardiotoxicity from
capecitabine resembles that of intravenous 5-FU
(≈5%). Cardiac comorbidity, hypercholesterolaemia
and current smoking were associated with
development of cardiotoxicity.
INTRODUCTION
Capecitabine is an oral prodrug of 5-
ﬂuorouracil (5-FU) that is converted to 5-FU
in a three-stage process involving several
enzymes.1 The last step is catalysed by thymi-
dine phosphorylase.1 Many tissues throughout
the body express thymidine phosphorylase,
but some human carcinomas express this
enzyme in higher concentrations than sur-
rounding normal tissues.1 This in theory
should increase the concentration of 5-FU at
the tumour site and decrease the concentra-
tion of 5-FU in healthy tissues resulting in less
side effects.1
Capecitabine is licensed for adjuvant treat-
ment in patients with colon cancer stage III
and for the treatment of metastatic colorectal
cancer, metastatic breast cancer and advanced
gastric cancer (combination therapy). The
main side effects from capecitabine are
hand-and-foot syndrome, diarrhoea, stoma-
titis, fatigue, anorexia, nausea and vomiting,
abdominal pain, myelosuppression, hyperbilir-
ubinemia and cardiotoxicity.2–5
Case reports of cardiotoxicity after adminis-
tration of capecitabine are similar to those
Strengths and limitations of this study
▪ Our study is a large single-centre study, includ-
ing all patients with breast cancer treated with
capecitabine over a 10-year period.
▪ The primary end point, cardiotoxicity, is mainly
diagnosed on the basis of subjective symptoms
(chest pain, dyspnoea, palpitations) which may
cause information bias.
▪ In spite of a relatively large sample size, the
number of events is low which limit the power of
the logistic regression analyses used to analyse
for risk factors.
▪ Our study is a retrospective clinical study. The
patients’ history records are incomplete with
respect to information on risk factors for cardio-
vascular disease (hypertension, hypercholesterol-
aemia, diabetes and smoking) and baseline ECG.
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seen with intravenous 5-FU treatment with chest pain as
the predominant manifestation.6–14 Other less frequent
clinical manifestations are arrhythmias, myocardial infarc-
tion, heart failure, cardiogenic shock and sudden
death.15–19 Cardiotoxicity from 5-FU occurs with an inci-
dence of 0.55–19.9%.15 There are few studies of capecita-
bine cardiotoxicity with incidences ranging from 3% to
35%.20–24
We aimed to study the pattern and incidence of symp-
tomatic cardiotoxicity in women with metastatic breast
cancer treated with capecitabine and to identify poten-
tial risk factors for capecitabine-induced cardiotoxicity.
MATERIALS AND METHODS
Selection of patients
We included patients with metastatic breast cancer con-
secutively treated with capecitabine from 1 January 2002
to 31 December 2012. Inclusion criteria were woman,
metastatic breast cancer and capecitabine treatment
(±trastuzumab). The chemotherapy regimen was capeci-
tabine 2000 mg/m² divided in two daily doses for
14 days followed by 1 week off.
Data collection
Approval from the Danish Data Protection Agency was
obtained. We collected data from medical records on
age, height, weight, body surface area, capecitabine dose,
cardiotoxicity, cardiac comorbidity (a history of previous
acute myocardial infarction, ischaemic heart disease,
arrhythmias, heart failure or reduced ejection fraction),
risk factors for ischaemic heart disease (a history of
hypertension or intake of antihypertensive drugs,
smoking status, a history of hypercholesterolaemia or
intake of lipid lowering drugs, a history of diabetes or
intake of antidiabetics), ECG (before treatment start and
if symptoms), haemoglobin levels, creatinine levels and
previous treatment with anthracyclines, trastuzumab,
breast and thoracic radiotherapy. Renal function (esti-
mated glomerular ﬁltration rate, eGFR) was estimated by
the Chronic Kidney Disease Epidemiology Collaboration
equation for Caucasian women incorporating age and
plasma creatinine concentrations. All the collected data
were prospectively selected.
Registration of symptoms and identification of cases with
cardiotoxicity
Before start of chemotherapy and before each cycle
adverse events were scored according to NCI/CTCAE
V.3.0. ECGs were performed before the ﬁrst cycle of
capecitabine and at clinical suspicion of cardiotoxicity.
Medical records were reviewed by one of the authors.
Cardiotoxicity was deﬁned as signiﬁcant symptoms of
likely cardiac origin (chest pain or acute myocardial
infarction (conﬁrmed with elevation in troponins over
the cut-off point), palpitations, dyspnoea of likely
cardiac origin and incompensation) and/or changes on
ECG that started during treatment with capecitabine
and was not present before treatment start. Cases with
suspected cardiotoxicity were further reviewed by one
cardiologist (MV-N) who made the ﬁnal decision to clas-
sify the case as cardiotoxicity or not. All patients were
followed to cessation of capecitabine. End points were
evaluated non-blinded, and the investigators had access
to patients’ medical record.
Statistics
Mann–Whitney U test was used to compare differences
in age between patients with cardiotoxicity and
patients without cardiotoxicity. Fisher’s exact test and
χ2 test were used to analyse differences in numeric vari-
ables between the two groups. χ2 test for trend were
used to analyse differences for ordinal variables.
Possible risk factors for cardiotoxicity were tested using
univariate binomial logistic regression and adjusted for
age with multivariate binomial logistic regression. In
order to test the robustness of the data and due to
missing data, sensitivity analyses were performed for
variables that tended to be signiﬁcant or were signiﬁ-
cant in univariate analyses. Sensitivity analyses were
performed both with multiple imputation and as worst-
case and best-case scenarios for one variable at a time.
Owing to the low number of events (=22), the poten-
tial risk of over ﬁtting of the statistical models and the
risk of collinearity among the covariates, we only
adjusted for age in the multivariate logistic regression
analyses. C statistics were performed for variables that
were signiﬁcant in univariate logistic regression ana-
lyses. p Values below 0.05 were regarded signiﬁcant.
IBM SPSS software V.21 was used for all analysis.
RESULTS
Study population
A total of 452 consecutive women with metastatic breast
cancer were eligible for analysis (ﬁgure 1). Patient
characteristics are listed in table 1. The median age was
63 years, 333 patients initially (74%) received 100%
dose, while 84 patients (19%) were treated with 75%
dose and 26 patients (6%) were treated with 50% dose,
respectively. Totally, 242 patients (54%) had previously
received treatment with anthracyclines, 54 patients
(12%) were treated previously or concurrent with trastu-
zumab, while 132 patients (29%) had a history of left-
sided breast irradiation. Radiotherapy was given
∼3 months after the primary diagnosis of breast cancer
and the mean time from diagnosis to start of capecita-
bine was 4 years (0.9–58 years). Forty-two patients
(9.3%) had cardiac comorbidities prior to initiation of
treatment. Of these, 6 (1%) had a history of ischaemic
heart disease while 37 (8%) had other types of cardiac
disease, including atrial ﬁbrillation (n=13), supraventri-
cular tachyarrhythmia (n=3), pericardial exudatives
(n=3), epirubicin-induced cardiomyopathy (n=3), atrio-
ventricular blocks (n=1), aortic valve disease (n=1) and
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reduced left ventricular ejection fraction of unknown
cause (n=4).
Cardiotoxicity
Twenty-two cases of symptomatic cardiotoxicity (4.9%)
(95% CI 2.91% to 6.89%) were identiﬁed from medical
records (see online supplementary table). The most
common symptoms were chest pain (13 patients) fol-
lowed by dyspnoea (9 patients) and palpitations (2
patients) (ﬁgure 2). Of these 22 patients, 11 (50%) had
changes on ECG. Five patients had atrial ﬁbrillation
(one paroxysmal and four new onset), while three
patients had ST deviations and two patients developed
negative or ﬂuctuating T-waves. Of the 13 patients with
chest pain, 2 (0.4%) had elevated troponins and were
classiﬁed as acute myocardial infarctions. One patient
(0.2%) with dyspnoea and progressing chest pain devel-
oped cardiac arrest with lethal outcome.
First occurrence of cardiotoxicity was in the ﬁrst cycle
for 11 patients (50%), the second cycle for four patients
(18%), the third cycle for 3 patients (14%) and the
fourth cycle for 1 patient (4.5%), while three patients
(14%) had late occurrence of cardiotoxicity (8th, 9th
and 12th cycle).
Cardiac therapy was initiated in 10 of the 22 patients
with cardiotoxicity (see online supplementary table),
while 6 were retreated with capecitabine. Three patients
were retreated at the same dose intensity without initi-
ation of cardiac therapy, two were retreated at the same
dose intensity, but received cardiac therapy with verap-
amil, and one patient were treated at reduced dose. The
three patients treated with full dose and no initiation of
cardiac therapy all had recurrent symptoms at retreat-
ment, while one patient treated with verapamil had
recurrent symptoms. The other two patients, one treated
with verapamil and one treated at reduced dose inten-
sity, did not have symptoms at retreatment.
Seven events of cardiotoxicity occurred in the sub-
group of patients with cardiac comorbidity (n=42)
(16.7%), while 15 patients in the subgroup of patients
with apparently no cardiac comorbidity (n=410) devel-
oped cardiotoxicity (3.7%).
Risk factors for symptomatic cardiotoxicity
In univariate logistic regression analyses, cardiac
comorbidity (p=0.001), hypercholesterolaemia (p=0.005)
and current smoking (p=0.023) were risk factors for cardi-
otoxicity (table 2), and they remained signiﬁcant after
adjustment for age with multivariate logistic regression.
Patients with cardiac comorbidity were 5.5 times (95% CI
2.0 to 14.8) more likely to develop cardiotoxicity than
patients without cardiac comorbidity. In the subgroup of
patients with apparently no cardiac comorbidity, hyper-
cholesterolaemia (p=0.035) and current smoking
(p=0.020) were signiﬁcant risk factors in univariate ana-
lyses and remained signiﬁcant after adjustment for age
(table 2).
Sensitivity analyses were performed for variables sig-
niﬁcant in the univariate analyses. In the entire study
group, hypercholesterolaemia, cardiac comorbidity and
current smoking remained signiﬁcant risk factors after
multiple imputation of missing values (p=0.008, p=0.001
and p=0.023, respectively) and after imputation with
worst-case and best-case scenarios (hypercholesterol-
aemia p=0.005 (best-case), p=0.032 (worst-case); cardiac
comorbidity p=0.007 (worst-case), p=0.001 (best-case);
current smoking p=0.045 (worst-case), p=0.032 (best-
case)). In the subgroup of patients with apparently no
cardiac comorbidity, current smoking remained signiﬁ-
cant after both multiple imputation analyses (p=0.021)
and worst-case and best-case analyses (p=0.025 and
p=0.042, respectively), while hypercholesterolaemia was
unaffected by multiple imputation (p=0.043) but suscep-
tible to worst-case and best-case analyses. The p value for
the univariate regression analysis was signiﬁcant
(p=0.035) when cases with missing data were imputed
with best-case scenario (none having hypercholesterol-
aemia) but became insigniﬁcant (p=0.132) in worst-case
scenario (all having hypercholesterolaemia).
C statistics: predictors of symptomatic cardiotoxicity
The ability of the variables, cardiac comorbidity, hyper-
cholesterolaemia and current smoking, to discriminate
between patients that will develop symptomatic cardio-
toxicity and those who will not was tested with c-statistics.
In unselected patients, the presence of cardiac
comorbidity was a poor predictor of symptomatic cardio-
toxicity (c=0.617 (95% CI 0.483 to 0.754), p=0.061), as
was the presence of hypercholesterolaemia (c=0.662
(95% CI 0.478 to 0.766), p=0.072) and smoking status
(c=0.651 (95% CI 0.523 to 0.779), p=0.031). In the sub-
group of patients with apparently no cardiac comorbid-
ity, the presence of hypercholesterolaemia (c=0.601
Figure 1 Flow diagram.
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(95% CI 0.427 to 0.775), p=0.216) and smoking status
(c=0.691 (95% CI 0.526 to 0.857), p=0.031) were poor
factors to discriminate between patients who will develop
cardiotoxicity and those who will not.
DISCUSSION
Incidence of symptomatic cardiotoxicity
We observed an incidence of symptomatic cardiotoxicity
from capecitabine at ≈5% in women with metastatic
Table 1 Patient characteristics
All patients
(n=452)
Patients with
cardiotoxicity (n=22)
Patients without
cardiotoxicity (n=430)
p Value*Characteristics No. (%) No. (%) No. (%)
Age (n=452)
Median 63 63 63 0.742
Range 28–88 36–82 28–88
Capecitabine dose (n=443)
50% 26 (6) 1 (5) 25 (6) 0.636
75% 84 (19) 6 (27) 78 (18)
100% 333 (74) 15 (68) 318 (74)
IHD (incl. previous ACS) (n=436) 6 (1) 0 6 (1) 1.000
Other cardiac diseases (n=436) 37 (8) 7 (32) 30 (7) 0.000
ECG at treatment start† (n=161)
Normal 132 (29) 9 (41) 123 (29) 0.454
Abnormal 29 (6) 3 (14) 26 (6)
Hypertension (n=442) 126 (28) 9 (41) 117 (27) 0.186
Hypercholesterolaemia (n=390) 53 (12) 7 (32) 46 (11) 0.002
Diabetes mellitus (n=435) 21 (5) 1 (5) 20 (5) 1.000
Smoking status (n=371)
Current smoker 105 (23) 9 (41) 96 (22) 0.264
Former smoker 66 (15) 4 (18) 62 (14)
Never smoked 200 (44) 5 (23) 195 (45)
BMI (n=382)
Underweight (BMI <18.5) 21 (5) 3 (14) 18 (4) 0.337
Normal (BMI 18.5–24.9) 208 (46) 8 (36) 200 (47)
Overweight (BMI 25.0–29.9) 109 (24) 9 (41) 100 (23)
Obese (BMI > 29.9) 44 (10) 0 44 (10)
Number of risk factors for IHD‡ (n=452)
0 131 (29) 3 (14) 128 (30) 0.005
1 182 (40) 8 (36) 174 (41)
2 90 (20) 5 (23) 85 (20)
3 32 (7) 3 (14) 29 (7)
4 17 (4) 3 (14) 14 (3)
5 0 0 0
Previous treatment with anthracyclines
(n=444)
242 (54) 9 (41) 233 (54) 0.189
Previous or concurrent treatment with
trastuzumab (n=403)
54 (12) 3 (14) 51 (12) 0.752
Previous breast irradiation (n=431) 275 (61) 8 (36) 267 (62) 0.052
Left side 132 (29) 5 (23) 127 (30) 0.218
Right side 115 (25) 1 (5) 114 (27)
Bilateral 25 (6) 2 (9) 23 (5)
Side unknown 3 (1) 0 3 (1)
Previous thoracic irradiation (n=407) 96 (21) 4 (18) 92 (21) 1.000
Anemia§ (n=437) 126 (28) 3 (14) 123 (29) 0.164
eGFR (n=429)
Low (<60 mL/min/1.73 m2) 71 (17) 6 (27) 65 (15) 0.105
Normal (≥60 mL/min/1.73 m2) 358 (79) 13 (59) 345 (80)
*p Value for the statistical tests of differences between patients with cardiotoxicity and patients without cardiotoxicity.
†All patients do routinely have ECG taken before treatment start and all ECGs are routinely seen by doctors, but not all ECGs were available
in the medical records.
‡Risk factors for IHD include hypertension, hypercholesterolaemia, diabetes mellitus, smoking and BMI.
§Defined according to the WHO: Hgb<7.4 mmol/L for non-pregnant women.
ACS, acute coronary syndrome; BMI, body mass index; eGFR, estimated glomerular filtration rate; IHD, ischaemic heart disease.
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breast cancer which is similar to incidences reported in
previous studies of men and women treated with capeci-
tabine,22–24 although some studies have reported lower20
or higher incidences.21 The difference in incidences
in-between studies may be due to different risk proﬁles
in the study populations. Moreover, prospective studies
with regular cardiac assessments may detect more cardi-
otoxicity since they may identify asymptomatic patients
and patients with mild symptoms.
The incidence of symptomatic cardiotoxicity in our
study and other studies of capecitabine cardiotoxicity
is within the range of incidences of symptomatic cardi-
otoxicity in studies with 5-FU15 21 24–26 and a large
study found similar incidences for the two treat-
ments.24 However, a prospective study with 644
patients reported similar incidences of cardiotoxicity
for capecitabine and continuous 5-FU infusion sche-
dules, but a lower incidence for short (bolus) 5-FU
infusion schedules.22
Pattern of symptomatic cardiotoxicity
The most common event of symptomatic cardiotoxicity was
chest pain, which was the main symptom in 59% of the 22
cases. Most of the patients with chest pain had normal
ECG and normal coronary enzymes, and severe events,
such as acute myocardial infarction and cardiac arrest with
lethal outcome, were rare. This pattern is in concordance
with other studies,15 and the sudden onset of chest pain
and the rare occurrence of life-threatening complications
correspond well to the theory of ﬂuoropyrimidine-induced
vasospastic angina. Furthermore, the angiographically
normal arteries reported in several case reports6–8 11 and
the presence of silent ischaemic episodes on Holter record-
ings27 support this theory.
Retreatment of patients with symptomatic cardiotoxicity
Retreatment with capecitabine after occurrence of cardi-
otoxicity was attempted in 6 of 22 patients with little
success. Four patients had recurrent cardiac symptoms,
suggesting that retreatment should be carried out with
great precaution. However, a retrospective study of 668
patients20 and a prospective study of 644 patients22
treated with 5-FU or capecitabine reported a beneﬁt
from dose reduction and initiation of antiangina therapy
that prevented symptoms at retreatment in 9 of 12
patients and 12 of 15 patients, respectively. Their ﬁnd-
ings suggest that retreatment at reduced dose and with
appropriate antiangina therapy are feasible, however
close cardiac monitoring is crucial. Furthermore, nitro-
glycerine was effective to abolish symptoms of cardiotoxi-
city.20 In contrast, a small and non-randomised study
could not demonstrate an prophylactic effect of calcium
channel blockers on occurrence of cardiotoxicity.28
Larger studies with systematic, predeﬁned strategies for
dose reduction and initiation of antiangina therapy are
needed.
Risk factors for symptomatic cardiotoxicity
Patients with cardiac comorbidity were at increased risk
of symptomatic cardiotoxicity, which is in accordance
with four previous studies of 5-FU or capecitabine cardi-
otoxicity,21 25 27 29 while other studies found no
increased risk for patients with pre-existing heart
disease.23 30–33 While heart disease may be a risk marker
for cardiotoxicity, it is not a prerequisite for cardiotoxi-
city to occur. The patient who sustained cardiac arrest
and died in our study had no cardiac comorbidities and
no risk factors for ischaemic heart disease. Likewise,
severe cardiotoxicity has been reported for several
patients without cardiac comorbidity.11 34–37 Also, we
Figure 2 The distribution of the
different manifestations of
cardiotoxicity. The percentages
showed on each bar reflect the
distribution of symptoms among
the 22 patients with cardiotoxicity.
Proportion of patients with chest
pain without ECG changes
(n=10), chest pain with ECG
changes but not acute myocardial
infarction (n=1), acute myocardial
infarction (n=2), arrhythmia (n=4),
cardiac arrest (n=1), dyspnoea/
incompensation (n=3) and other
(n=1, with QT prolongation and
right bundle branch block).
Patients with more than one of
the manifestations (n=2) are
classified according to their
primary symptom.
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Table 2 Univariate and bivariate logistic regression models of risk factors for symptomatic cardiotoxicity
β coefficient (95% CI) OR (95% CI) p Value β coefficient (95% CI) OR (95% CI) p Value
Variable Univariate Bivariate: adjusted for age
All patients (N=452) (events=22)
Age* 0.01 (−0.03 to 0.04) 1.01 (0.97 to 1.05) 0.789 – – –
Hypercholesterolaemia† 1.42 (0.43 to 2.40) 4.12 (1.54 to 11.00) 0.005 1.42 (0.38 to 2.46) 4.14 (1.46 to 11.75) 0.008
Hypertension† 0.58 (−0.29 to 1.46) 1.79 (0.75 to 4.31) 0.192 0.60 (−0.33 to 1.52) 1.82 (0.72 to 4.57) 0.206
Diabetes† −0.07 (−2.12 to 1.99) 0.94 (0.12 to 7.32) 0.949 −0.11 (−2.17 to 1.96) 0.90 (0.11 to 7.13) 0.921
Smoking†
Current smoker 1.30 (0.17 to 2.42) 3.66 (1.19 to 11.21) 0.023 1.30 (0.18 to 2.42) 3.66 (1.19 to 11.22) 0.023
Former smoker 0.92 (−0.42 to 2.27) 2.52 (0.66 to 9.66) 0.179 0.92 (−0.43 to 2.27) 2.51 (0.65 to 9.67) 0.181
BMI* −0.05 (−0.16 to 0.06) 0.95 (0.85 to 1.06) 0.380 −0.05 (−0.16 to 0.07) 0.96 (0.85 to 1.07) 0.413
Previous irradiation of left breast† −0.14 (−1.05 to 0.78) 0.87 (0.35 to 2.18) 0.763 −0.13 (−1.05 to 0.80) 0.88 (0.35 to 2.22) 0.785
“Cardiac comorbidity”† 1.63 (0.67 to 2.59) 5.12 (1.96 to 13.39) 0.001 1.70 (0.70 to 2.69) 5.47 (2.02 to 14.80) 0.001
Anemia† −0.86 (−2.12 to 0.39) 0.42 (0.12 to 1.47) 0.176 −0.86 (−2.12 to 0.39) 0.42 (0.12 to 1.47) 0.176
eGFR* −0.01 (−0.03 to 0.02) 0.99 (0.97 to 1.02) 0.487 −0.01 (−0.03 to 0.02) 0.99 (0.97 to 1.02) 0.638
Previous anthracyclines† −0.58 (−1.43 to 0.29) 0.56 (0.24 to 1.34) 0.194 −0.73 (−1.77 to 0.31) 0.48 (0.17 to 1.36) 0.171
Previous or concurrent trastuzumab† 0.08 (−1.17 to 1.34) 1.08 (0.31 to 3.80) 0.903 0.11 (−1.17 to 1.41) 1.12 (0.31 to 4.09) 0.864
Dose of capecitabine* −0.01 (−0.03 to 0.02) 1.00 (0.97 to 1.02) 0.666 −0.01 (−0.03 to 0.02) 1.00 (0.97 to 1.02) 0.682
Previous thoracic irradiation† 0.08 (−1.08 to 1.24) 1.08 (0.34 to 3.44) 0.892 0.12 (−1.05 to 1.28) 1.12 (0.35 to 3.60) 0.847
Patients with no history of heart disease (n=399) (events=15)
Age* 0.001 (−0.04 to 0.05) 1.00 (0.96 to 1.05) 0.949 – – –
Hypercholesterolaemia† 1.32 (0.01 to 2.55) 3.75 (1.10 to 12.81) 0.035 1.34 (0.04 to 2.63) 3.81 (1.04 to 13.94) 0.043
Hypertension† 0.05 (−1.11 to 1.22) 1.05 (0.33 to 3.38) 0.929 0.04 (−1.17 to 1.25) 1.04 (0.31 to 3.51) 0.947
Diabetes† 0.48 (−1.61 to 2.57) 1.62 (0.20 to 13.10) 0.651 0.48 (−1.63 to 2.58) 1.61 (0.20 to 13.26) 0.658
Smoking†
Current smoker 1.64 (0.26 to 3.01) 5.13 (1.30 to 20.33) 0.020 1.63 (0.25 to 3.00) 5.09 (1.28 to 20.18) 0.021
Former smoker 0.18 (−2.10 to 2.46) 1.20 (0.12 to 11.76) 0.876 0.19 (−2.10 to 2.47) 1.21 (0.12 to 11.85) 0.872
BMI* −0.04 (−0.18 to 0.09) 0.96 (0.84 to 1.09) 0.530 −0.04 (−0.17 to 0.10) 0.96 (0.84 to 1.10) 0.578
Previous irradiation of left breast† −0.41 (−1.56 to 0.76) 0.67 (0.21 to 2.13) 0.495 −0.41 (−1.56 to 0.77) 0.67 (0.21 to 2.15) 0.497
Anemia† −1.62 (−3.51 to 0.43) 0.20 (0.03 to 1.54) 0.121 −1.62 (−3.51 to 0.43) 0.20 (0.03 to 1.54) 0.121
eGFR* 0.00 (−0.03 to 0.03) 1.00 (0.97 to 1.03) 0.876 0.01 (−0.03 to 0.05) 1.01 (0.97 to 1.05) 0.668
Previous anthracyclines† 0.67 (−0.39 to 1.72) 1.96 (0.68 to 5.60) 0.212 0.92 (−0.33 to 2.18) 2.52 (0.72 to 8.86) 0.150
Previous or concurrent trastuzumab† 0.42 (−0.87 to 1.72) 1.53 (0.42 to 5.60) 0.525 0.48 (−0.87 to 1.83) 1.62 (0.42 to 6.26) 0.484
Dose of capecitabine* −0.01 (−0.04 to 0.02) 0.99 (0.96 to 1.02) 0.573 −0.01 (−0.04 to 0.02) 0.99 (0.96 to 1.02) 0.579
Previous thoracic irradiation† 0.35 (−1.02 to 1.72) 1.42 (0.36 to 5.59) 0.621 0.40 (−0.99 to 1.79) 1.48 (0.37 to 5.96) 0.577
Bold p values indicate a significant difference (p<0.05).
*Scale variable.
†Categorical variable.
‘Cardiac comorbidity’, all types of heart disease; BMI, body mass index; eGFR, estimated glomerular filtration rate.
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found that a history of heart disease was a poor pre-
dictor of cardiotoxicity.
In the present study, hypercholesterolaemia and
current smoking were risk factors for symptomatic cardio-
toxicity in the entire study group and in the subgroup of
patients with no apparent cardiac comorbidity. Similarly,
a larger prospective study of 644 patients without cardiac
comorbidities reported that smoking was associated with
ECG changes in bivariate analyses.22 However, they found
no association between ECG changes and hyperlipid-
aemia.22 While Kosmas et al22 prospectively measured
cholesterol and triglyceride levels in blood; our study is
based on medical recordings. Thus, incomplete data with
risk of information bias is a limitation of the present
study. Both studies have a low number of events limiting
the statistical power, and multiple testing increases the
risk of false-positive results.
Previous treatment with potentially cardiotoxic therapy
with anthracyclines or previous or current treatment with
trastuzumab did not increase the risk of symptomatic car-
diotoxicity. However, two of three patients with
epirubicin-induced cardiomyopathy developed symptom-
atic cardiotoxicity during treatment with capecitabine, sug-
gesting that the degree of pre-existing heart damage may
be relevant. Patients with previous left-sided breast irradi-
ation were not at increased risk of cardiotoxicity in our
study. Similarly, a large prospective study of 5-FU cardio-
toxicity found that previous breast irradiation was not a
risk factor.25 The lack of association between other cardio-
toxic therapies and capecitabine-induced cardiotoxicity
suggests that the mechanisms behind these cardiotoxicities
are different. Moreover, radiation-induced cardiovascular
disease may be a late event.38 In our study, the mean time
from chest irradiation to capecitabine start was 4 years.
Methodological considerations
The predominant manifestation of symptomatic cardio-
toxicity from ﬂuoropyrimidines is chest pain followed by
other subjective symptoms and ECG changes or other
objective signs of cardiotoxicity are not always present.
In our study, only ∼50% of the patients had objective
signs (mostly ECG changes) of cardiotoxicity. Thus, the
event (cardiotoxicity) was based mainly on subjective
symptoms and is therefore affected by the patient’s own
perception and reaction to the symptoms and the physi-
cian’s assessment of the patient’s symptoms. Patients and
physicians may pay more attention to cardiac symptoms
if the patient has heart disease before treatment start.
These factors may explain some of the difference in inci-
dence in-between studies. Research in new and sensitive
cardiac biomarkers like, for example, copeptin to detect
myocardial ischaemia is needed.39
In spite of a relatively large sample size, the number
of events is low (22 events) leading to wide CIs, low stat-
istical power and increased risk of type II statistical
errors. With respect to the logistic regression analyses,
the low number of events limits the number of covariates
allowed in the model. The low number of events and
multiple testing (increasing the risk of false-positive
results) are weaknesses of most studies analysing risk
factors, and it makes the conclusions that can be drawn
from these studies less valid.
Like most other large studies on this subject, our study
is retrospective which may results in underestimation of
the incidence of cardiotoxicity due to incomplete data
and overlooking patients with mild symptoms and
asymptomatic patients. Missing data affect power and if
not missing at random, they may cause bias. We dealt
with the missing data by sensitivity analyses with worst-
case and best-case scenarios and with multiple imput-
ation. The sensitivity analyses showed that missing data
had little inﬂuence on our study results.
A major limitation is that baseline ECGs were only pre-
served for 36% of the patients. Among the 11 patients
with ECG changes during capecitabine treatment, 2 had
missing baseline ECGs.
CONCLUSIONS
The incidence of symptomatic cardiotoxicity from capeci-
tabine of ≈5% is close to that of 5-FU with incidences of 1–
5% in larger studies. Our study results suggest that cardiac
comorbidity and current smoking are risk factors for symp-
tomatic cardiotoxicity. Whether smoking cessation can
prevent some cases of symptomatic cardiotoxicity deserves
further investigations. All the identiﬁed risk factors were
poor predictors of symptomatic cardiotoxicity and initial
optimal cardiac treatment, information about the risk and
follow-up if symptoms present are the options today.
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